Expiry Dates: Diagnosing a Dying Strategy Before the Market Writes the Obituary
The Patent That Runs Out
Consider what happens when a pharmaceutical company develops a breakthrough drug. For years, the patent protects its monopoly, and margins are extraordinary. Then the patent expires. Generic manufacturers flood the market, pricing power evaporates, and what was once a license to print money becomes a commodity business. The drug itself hasn't changed — its chemistry is identical. What changed is access. Everyone can now make it, so no one profits from it.
Trading edges behave the same way. A strategy works because it exploits some inefficiency: a behavioral bias, a structural flow, an informational gap. The moment that inefficiency becomes widely known — published in an academic paper, discussed on financial television, encoded into a commercial backtesting platform — the crowd arrives. And crowds, by definition, consume the very mispricing they chase. The edge doesn't break dramatically. It bleeds out slowly, one basis point at a time, as competition compresses the spread between entry and fair value.
Decay Follows a Curve, Not a Cliff
Physicists describe radioactive decay with a half-life: the time required for half of a substance to transform. Edges decay along a similar curve, though rarely with such mathematical elegance. The returns don't vanish overnight. They attenuate — first the win rate slips from 62% to 57%, then the average winner shrinks while the average loser quietly fattens. Traders who expect a clean break are looking for the wrong signal. The strategy that dies loudly is rare; the strategy that dies by a thousand incremental degradations is the norm.
This is why the psychological trap is so pernicious. A gradual decline looks, from inside the position log, like an ordinary losing streak. And every strategy has losing streaks. The trader who abandons a healthy system during a normal drawdown destroys value just as surely as the one who rides a dead system into the ground. Distinguishing the two requires diagnostics, not intuition.
Three Diagnostics That Separate Rough Patches from Terminal Decline
Fill quality degradation. Your backtest assumed certain prices. Your broker confirms them — or doesn't. Track your realized entry prices against the midpoint at order submission. When an edge is alive, you're often on the right side of the spread; market participants haven't yet recognized the pattern you're trading. When the edge is dying, you become the liquidity someone else is waiting for. Slippage drift of even a few basis points per trade can erase a strategy whose expectancy was modest to begin with. Log it. Chart it. Treat a four-week deterioration in fill quality as a red flag, not noise.
Drawdown character. Healthy strategies produce drawdowns that are shallow, quick, and consistent with historical distribution. A dying strategy produces drawdowns that feel different in shape: longer recoveries, deeper troughs, and — critically — recovery through luck rather than through the mechanism that generated the original profits. Ask yourself honestly: is the system working and losing, or is it broken and occasionally getting bailed out?
Correlation creep. When an edge becomes crowded, its trades start appearing everywhere. If your long/short rotation model suddenly overlaps heavily with a popular ETF's holdings, or your breakout signals fire in lockstep with the crowd, your counterparties have changed. You're no longer trading against an inattentive participant; you're trading against a mirror. Crowded edges have compressed payoffs and fat tails, because unwinds are synchronized.
The Reflexive Trap of Success
There is a deeper irony here, one familiar to readers of our Macro Strategy coverage: the very success of a strategy accelerates its demise. Profits attract capital. Capital flows into the same signals, the same setups, the same crowded exits. The strategy's popularity becomes the mechanism of its destruction — a small-scale version of the reflexive cycles that inflate and deflate entire market narratives. Your edge, in other words, is partially self-consuming. This isn't a flaw in your system. It's a structural feature of markets that price discovery exists precisely to eliminate free lunches.
Building the Exit Before You Need It
The practical prescription is unglamorous. Maintain a rolling performance log that tracks expectancy, fill quality, and slippage against baseline — not just P&L. Define, in advance, the objective conditions under which you will reduce size, pause, or retire a strategy. Write them down when you're calm, because you will not think clearly when the drawdown arrives. And allocate research time the way a drug company allocates R&D: the pipeline of future edges must be under development while the current one is still profitable, not after it flatlines.
No strategy is forever. The traders who last aren't those who found the holy grail — they're those who treated every edge as a depreciating asset, monitored its decay with the same rigor they monitor their positions, and rotated into new territory while the old one still paid. In markets, as in patents, the money is made before everyone else gets the recipe.
